DMAC

DiaMedica Therapeutics Inc. NASDAQ Listed Aug 3, 2012

Healthcare ·Biotechnology ·US · diamedica.com

$6.53

After hrs $6.45 +0.00%

Mkt Cap $351.9M

52w Low $3.48 44.0% of range 52w High $10.42

50d MA $6.87 200d MA $7.07

P/E (TTM) -8.8x

EV/EBITDA -10.4x

P/B 5.2x

Debt/Equity 0.0x

ROE -58.4%

P/FCF -12.9x

RSI (14) —

ATR (14) —

Beta 1.15

50d MA $6.87

200d MA $7.07

Avg Volume 197.3K

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

SIC Code

2834

CIK (SEC)

1401040

Phone

763 612 6755

Two Carlson Parkway · Minneapolis, MN 55447 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 6, 2026	AMC	-0.17	-0.19	-11.8%	6.52	-1.2%	+0.2%	-3.2%	—	—	—	—
Mar 30, 2026	AMC	-0.17	-0.17	+0.0%	6.64	+7.5%	+2.0%	-5.2%	+0.9%	+2.2%	-1.1%	—
Nov 12, 2025	AMC	-0.15	-0.17	-13.3%	6.31	-6.3%	-14.1%	+9.4%	+8.1%	+7.6%	+5.8%	—
Aug 12, 2025	AMC	-0.18	-0.18	+0.0%	5.22	-6.1%	+14.9%	+0.2%	+0.3%	-4.5%	+0.2%	—
May 13, 2025	AMC	-0.18	-0.18	+0.0%	3.98	-1.8%	+0.5%	+1.8%	+3.2%	+1.7%	-3.0%	—
Mar 17, 2025	AMC	-0.17	-0.18	-5.9%	5.99	+0.2%	-13.0%	+0.6%	-1.9%	-3.1%	-0.6%	—
Nov 13, 2024	AMC	-0.15	-0.15	+0.0%	4.26	+0.7%	-3.3%	-2.7%	+3.5%	-2.7%	-0.5%	—
Aug 7, 2024	AMC	-0.16	-0.13	+18.8%	3.25	+0.9%	+3.1%	+6.0%	-0.6%	+1.4%	-2.8%	—
May 8, 2024	AMC	-0.16	-0.14	+12.5%	3.47	-2.9%	-6.3%	-4.0%	+2.2%	-5.3%	-0.3%	—
Mar 19, 2024	AMC	-0.14	-0.14	+0.0%	2.82	+1.4%	-1.8%	-2.9%	+2.2%	-2.5%	+1.5%	—
Nov 13, 2023	AMC	-0.14	-0.12	+14.3%	2.34	-9.4%	+6.8%	-2.0%	-2.9%	+4.6%	-2.8%	—
Aug 14, 2023	AMC	-0.22	-0.16	+27.3%	2.84	-4.2%	+4.6%	+3.7%	-7.8%	+1.1%	+1.7%	—
May 15, 2023	AMC	-0.16	-0.20	-25.0%	1.99	+1.0%	-11.1%	-1.1%	+20.6%	+6.6%	+24.4%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.01	$6.02	+0.2%	+0.3%	-4.5%	+0.2%	+4.0%	-1.2%
Jul 18	Craig-Hallum	Maintains	Buy → Buy	—	$3.93	$4.04	+2.8%	+6.4%	+8.6%	+1.3%	+12.0%	-5.2%
Jul 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.93	$4.04	+2.8%	+6.4%	+8.6%	+1.3%	+12.0%	-5.2%
Jul 18	Lake Street	Maintains	Buy → Buy	—	$3.93	$4.04	+2.8%	+6.4%	+8.6%	+1.3%	+12.0%	-5.2%
May 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.16	$4.24	+1.9%	+0.7%	-1.9%	+1.5%	-1.2%	+1.9%
Mar 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.21	$5.25	+0.8%	+0.6%	-1.9%	-3.1%	-0.6%	-7.7%
Nov 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.12	$4.16	+1.0%	-2.7%	+3.5%	-2.7%	-0.5%	+4.0%
Oct 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.50	$4.50	+0.0%	-1.8%	-3.8%	+4.9%	-0.2%	-1.1%
Aug 16	Oppenheimer	Maintains	Outperform → Outperform	—	$3.51	$3.46	-1.4%	+2.6%	-0.8%	+3.6%	+0.0%	+7.6%
Mar 21	Craig-Hallum	Maintains	Buy → Buy	—	$2.77	$2.80	+1.1%	-2.9%	+2.2%	-2.5%	+1.5%	-2.6%
Mar 21	Oppenheimer	Maintains	Outperform → Outperform	—	$2.77	$2.80	+1.1%	-2.9%	+2.2%	-2.5%	+1.5%	-2.6%
Jun 22	Oppenheimer	Upgrade	Perform → Outperform	—	$3.64	$3.85	+5.8%	+11.3%	+4.9%	+3.5%	-3.4%	-0.7%
Jul 7	Craig-Hallum	Maintains	Buy → Buy	—	$2.02	$1.27	-37.1%	-37.6%	+7.1%	-3.7%	-1.5%	+4.7%
Jul 7	Oppenheimer	Downgrade	Outperform → Perform	—	$2.02	$1.27	-37.1%	-37.6%	+7.1%	-3.7%	-1.5%	+4.7%
Jul 7	Lake Street	Maintains	Buy → Buy	—	$2.02	$1.27	-37.1%	-37.6%	+7.1%	-3.7%	-1.5%	+4.7%
Jun 30	Roth Capital	Maintains	Buy → Buy	—	$4.74	$4.66	-1.7%	-6.1%	-3.6%	-1.6%	-6.9%	+7.1%
Apr 9	Oppenheimer	Maintains	Outperform → Outperform	—	$9.40	$9.65	+2.7%	+5.4%	-5.7%	-1.4%	+3.5%	+3.1%
Apr 8	Oppenheimer	Maintains	Outperform → Outperform	—	$9.35	$9.45	+1.1%	+0.5%	+5.4%	-5.7%	-1.4%	+3.5%
Feb 17	Roth Capital	Maintains	Buy → Buy	—	$9.40	$10.54	+12.1%	+10.9%	-2.6%	+2.8%	-5.1%	-4.6%
Jul 8	Maxim Group	Maintains	Buy → Buy	—	$6.75	$7.28	+7.9%	+2.5%	-3.2%	-8.2%	-5.7%	+1.7%
May 15	Craig-Hallum	Maintains	Buy → Buy	—	$4.50	$4.69	+4.2%	+0.0%	+9.1%	-6.9%	+8.3%	-5.9%

Data updated apr 25, 2026 5:26am · Source: massive.com